<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02460861</url>
  </required_header>
  <id_info>
    <org_study_id>MD-URO-00021</org_study_id>
    <nct_id>NCT02460861</nct_id>
  </id_info>
  <brief_title>Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy</brief_title>
  <acronym>iPROLOGX</acronym>
  <official_title>Intraoperational Prostate Loge Biopsies (iPROLOGX) After Radical Prostatovesiculectomy (RPVE) in Prostate Cancer (PCA) Patients for Molecular Tumor Marker Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Magdeburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital Gronau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Magdeburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is about the detection of occult tumor cells in surgical margins of radical&#xD;
      prostatovesiculectomy by analysing the methylation status of Glutathione S-transferase P 1&#xD;
      (GSTP1). After gland excision specimens are obtained from 9 defined areas of the prostatic&#xD;
      fossa. The biopsies are divided into two parts. One part used for histopathological analysis&#xD;
      and the other part for moleculargenetic analysis. Results will be correlated e.g. with tumor&#xD;
      stage, Gleason Score and prostate specific antigen (PSA).&#xD;
&#xD;
      The prostate-cancer-negative control group with bladder cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project is about the detection of occult tumor cells in surgical margins of radical&#xD;
      prostatovesiculectomy by analysing the methylation status of Glutathione S-transferase P 1&#xD;
      (GSTP1). After gland excision specimens are obtained from 9 defined areas of the prostatic&#xD;
      fossa. The biopsies are divided into two parts. One part used for histopathological analysis&#xD;
      and the other part for moleculargenetic analysis. Results will be correlated e.g. with tumor&#xD;
      stage, Gleason Score and prostate specific antigen (PSA).&#xD;
&#xD;
      The prostate-cancer-negative control group with bladder cancer.&#xD;
&#xD;
      DNA ISOLATION&#xD;
&#xD;
      DNA from biopsies stored by -80°C was isolated by using innuPREP DNA mini Kit (Analytik Jena,&#xD;
      Jena, Germany) following protocol 1 of the manufacturer's instructions. DNA was eluted with&#xD;
      50 µl elution buffer. Concentration and purity were analysed by using Nanodrop 2000.&#xD;
&#xD;
      DNA BISULFITE MODIFICATION&#xD;
&#xD;
      DNA was modified by using EpiTect Bisulfite Kit (QIAGEN, Hilden, Germany) according to&#xD;
      manufacturer's instructions. Samples were eluted once with 20 µl elution buffer.&#xD;
&#xD;
      QUANTITATIVE METHYLATION SPECIFIC PCR&#xD;
&#xD;
      Methylation status of GSTP1 is analysed by quantitative methylation-specific PCR (Q-MSP)&#xD;
      using StepOnePlus Real-Time PCR System and StepOne Software v2.1 from Applied Biosystems&#xD;
      (Darmstadt, Germany). Q-MSP was performed in duplicate analysing genes Actin and GSTP1. The&#xD;
      primers' and testing probes' sequences used to amplify and detect hypermethylated GSTP1 were:&#xD;
      5'-AgTTgCgCggCgATTTC (forward primer), 5'-gCCCCAATACTAAATCACgACg (reverse primer) and&#xD;
      5'-CggTCgACgTTCggggTgTAgCg (taqman probe), labelled with fluorescence dye FAM. The primers'&#xD;
      and testing probes' sequences used to amplify and detect Actin were:&#xD;
      5'-TggTgATggAggAggTTTAgTAAgT (forward primer), 5'-AACCAATAAAACCTACTCCTCCCTTAA (reverse&#xD;
      primer),5'-ACCACCACCCAACACACAATAACAAACACA (taqman probe), labelled with fluorescence dye VIC.&#xD;
&#xD;
      The Q-MSP was carried out at 50°C for 2 min., 95°C for 15 min. followed by 50 cycles of 95°C&#xD;
      for 1s and 60°C for 1 min. As a positive control bisulfite-converted DNA of DU145 and LNCap&#xD;
      were used. Blank reactions with destillated water, which replaced DNA, served as negative&#xD;
      control (NTC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Methylation status of GSTP1</measure>
    <time_frame>2 years</time_frame>
    <description>Methylation status of GSTP1 is analysed by quantitative methylation-specific PCR (Q-MSP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Histopathology of prostate fossa biopsies</measure>
    <time_frame>2 years</time_frame>
    <description>Histopathology of prostate fossa biopsies (Prostata cancer positive or negative)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>PCA Magdeburg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prostate cancer conducted for RPVE with curative Intention, biopsies of the prostatic fossa in Magdeburg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conducted for CE in Male with bladder cancer or other indication for cystectomy but without prostate cancer in Magdeburg or Gronau, biopsies of the prostatic fossa in Gronau</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCA Gronau</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prostate cancer conducted for ETRARP with curative Intention, biopsies of the prostatic fossa</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsies of the prostatic fossa in Magdeburg</intervention_name>
    <description>intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg</description>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <arm_group_label>PCA Magdeburg</arm_group_label>
    <other_name>surgical biopsies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>RPVE</intervention_name>
    <description>Open Radical prostatovesiculectomy in Magdeburg</description>
    <arm_group_label>PCA Magdeburg</arm_group_label>
    <other_name>surgical prostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>ETRARP</intervention_name>
    <description>Robotassisted Radical prostatovesiculectomy in Gronau</description>
    <arm_group_label>PCA Gronau</arm_group_label>
    <other_name>surgical prostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CE</intervention_name>
    <description>Open cystectomy in Magdeburg/Gronau</description>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <other_name>surgical cystoprostatectomy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsies of the prostatic fossa in gronau</intervention_name>
    <description>intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau</description>
    <arm_group_label>Non-prostate cancer Magdeburg/Gronau</arm_group_label>
    <arm_group_label>PCA Gronau</arm_group_label>
    <other_name>surgical biopsies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for patients with prostate adenocarcinoma:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  sex: male&#xD;
&#xD;
          -  diagnosis: prostate adenocarcinoma&#xD;
&#xD;
          -  treatment: radical prostatovesiculectomy&#xD;
&#xD;
          -  period of treatment: 11/30/2011 - 10/15/2013&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  sex: female&#xD;
&#xD;
          -  diagnosis: no prostate adenocarcinoma&#xD;
&#xD;
          -  treatment: no radical prostatovesiculectomy&#xD;
&#xD;
          -  period of treament: before 11/30/2011 or after 10/15/2013&#xD;
&#xD;
        Criteria for prostate adenocarcinoma negative control group:&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  sex: male&#xD;
&#xD;
          -  diagnosis: urothelial carcinoma&#xD;
&#xD;
          -  treatment: cysto-prostatectomy&#xD;
&#xD;
          -  period of treament: 12/14/2011 - 02/18/2014&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  sex: female&#xD;
&#xD;
          -  diagnosis: incidental prostate adenocarcinoma&#xD;
&#xD;
          -  treatment: no cysto-prostatectomy&#xD;
&#xD;
          -  period of treatment: before 12/14/2011 or after 02/18/2014&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Schostak, Prof.Dr.med.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Magdeburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Gronau</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University Clinic Otto von Guericke University Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen-Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>May 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2015</study_first_posted>
  <last_update_submitted>May 29, 2015</last_update_submitted>
  <last_update_submitted_qc>May 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Magdeburg</investigator_affiliation>
    <investigator_full_name>Johann J. Wendler, MD</investigator_full_name>
    <investigator_title>Dr. med.</investigator_title>
  </responsible_party>
  <keyword>Prostate Cancer</keyword>
  <keyword>Molecular staging</keyword>
  <keyword>GSTP1</keyword>
  <keyword>Surgical margins</keyword>
  <keyword>prostatovesiculectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

